Attp: Time to Tumor Progression

Table 1S: Response to treatment

Primary Tumor Site / Prior Gemcitabine / Dose Level / No. of Cycles / Best Response / TTPa (Days)
Lung
1 / No / -2A / 1 / NEb / NE
2 / Yes / -1A / 6 / SDc / 138
3 / Yes / 2A / 2 / NE / NE
4 / No / 1B / 4 / SD / 111
5 / No / 1B / 2 / SD / 128
6 / No / 2B / 2 / PDd / 50
7 / Yes / 2BExp / 1 / PD / 25
8 / No / 3B / 1 / NE / NE
Pancreas
1 / Yes / 1B / 4 / SD / 115
2 / Yes / 1B / 3 / SD / 83
3 / Yes / 2B / 4 / SD / 111
4 / No / 2BExp / 1 / NE / NE
5 / Yes / 2BExp / 2 / SD / 93
6 / Yes / 2BExp / 2 / PD / 48
Bladder
1 / Yes / -1A / 1 / NE / NE
2 / Yes / 1A / 3 / PD / 64
3 / Yes / 2B / 1 / PD / 17
4 / Yes / 2B / 4 / SD / 112
5 / Yes / 3B / 3 / SD / 95
Breast
1 / No / -1A / 1 / PD / 31
2 / No / -1A / 4 / SD / 84
3 / Yes / 2A / 2 / NE / NE
4 / No / 2Bf / 2 / PD / 48
Gallbladder
1 / No / 1A / 2 / PD / 57
2 / No / 1B / 2 / PD / 48
3 / No / 2Bf / 6 / PRe / 299
Others
Anus / No / 2B / 2 / PD / 46
Cervix / No / 2B / 8 / SD / 240
Colon / No / 1A / 1 / PD / 30
Gastroesophageal Junction / No / 1B / 3 / SD / 62
Gastrointestinal Stroma / No / 2B / 2 / PD / 59
Merkel Cell / No / 1A / 2 / PD / 36
Rectum / No / -1A / 1 / PD / 17
Stomach / No / 1A / 5 / SD / 106
Unknown Primary / No / 2BExp / 4 / SD / 102
Uterus / No / 2BExp / 4 / SD / 202

aTTP: Time to tumor progression

bNE: Not evaluable

cSD: Stable disease

dPD: Progressive disease

ePR: Partial response

fMistakenly, received treatment at dose level 3B for day1/cycle1; but after that received appropriate treatment at dose level 2B

2BExp: Expansion arm of dose level 2B